Patent ID: 7119084
Filing Date: 2006-10-10
Classification: A61P,C07D

Abstract:
1. A method of treating disease conditions selected from the list consisting of benign or malignant tumors, diseases of the airways and lungs, diseases of the gastrointestinal tract, the bile duct and the gall bladder said method comprising administering to a patient in need of such treatment an effective amount of a compound of general formula (I): wherein R R R a cyclobutyl, cyclopentyl or cyclohexyl group which is substituted in each case by a group R an azetidin-3-yl group which is substituted in the 1 position by the group R a pyrrolidin-3-yl group which is substituted in the 1 position by the group R a piperidin-3-yl group which is substituted in the 1 position by the group R a piperidin-4-yl group which is substituted in the 1 position by the group R or a tetrahydrofuran-3-yl, tetrahydropyran-3-yl or tetrahydropyran-4-yl group, R a hydroxy group, a C a methoxy group substituted by 1 to 3 fluorine atoms, an ethyloxy group substituted by 1 to 5 fluorine atoms, a C a C a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy or tetrahydropyran-4-yloxy group, a tetrahydrofuranyl-C a C or a C X denotes a nitrogen atom, and by the aryl groups mentioned in the definition of the above groups is meant in each case a phenyl group which is mono- or disubstituted by R by the heteroaryl groups mentioned in the definition of the above groups is meant a pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl group, while said heteroaryl groups are each mono- or disubstituted by the group R said pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl groups may be substituted in each case by one or two C unless otherwise stated, said alkyl groups may be straight-chained or branched, with the proviso that the compound 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-hydroxy-quinazoline is excluded, their tautomers, their stereoisomers, their mixtures and their pharmacueticalyl acceptable salts.